Meditech Development v. Solventum: NPWT Patent Case Transferred to San Antonio
Meditech Development, Inc. sued Solventum Corporation in the Western District of Texas alleging infringement of two negative pressure wound therapy patents covering products including V.A.C. Ulta, Veraflo, and SensaT.R.A.C. systems. After just 70 days, the case was transferred intra-district to the San Antonio Division on the parties' joint motion.
NPWT infringement action heads to San Antonio on joint motion
On March 26, 2026, Meditech Development, Inc. filed a patent infringement action against Solventum Corporation in the Western District of Texas, asserting US9186444B2 and US9138216B2. The accused products include Solventum's SensaT.R.A.C., VeraT.R.A.C., VeraT.R.A.C. Duo tubing, V.A.C. Ulta and V.A.C. Ulta 4 NPWT units, and associated wound therapy lines including Veraflo, Prevena, and AbThera Therapy, as well as related wound dressings and topical wound solutions.
The recorded basis of termination in the Midland Division is 'Case Transferred.' The docket order states that the Court granted the parties' joint motion for intra-district transfer under 28 U.S.C. § 1404(b) and directed the Clerk to transfer the case to the San Antonio Division of the Western District of Texas without delay. The transfer was consensual — both parties filed the motion jointly — meaning no contested venue dispute was resolved on the merits.
The transfer was completed in 70 days from filing, before any substantive merits rulings. The fact that both parties jointly sought transfer suggests agreement that the San Antonio Division was a more appropriate venue within the same district. The merits of the infringement claims, claim construction, and any damages questions remain entirely open and will be litigated in the San Antonio Division. The specific reasons the parties preferred San Antonio over Midland are not disclosed in the available public record.
See Complete Case & Patent Analysis →Filing to Case Transferred in 70 days
70 days from filing to intra-district transfer — a swift procedural resolution before substantive merits litigation
US9186444B2 & US9138216B2 — Negative Pressure Wound Therapy Systems
Any company developing, manufacturing, or distributing negative pressure wound therapy units, tubing assemblies, wound dressings, or related therapy delivery systems should treat these two patents as active freedom-to-operate risks. The breadth of Solventum's accused product range — spanning multiple NPWT therapy brands and device generations — suggests the asserted claims may cover widely adopted NPWT configurations, not niche features.
Official order — verbatim text
The court's transfer order is purely procedural — it resolves only the question of which division within the Western District of Texas will adjudicate the case, granting the parties' joint motion under 28 U.S.C. § 1404(b). No merits determination, claim construction ruling, or infringement finding was made. The order leaves all substantive questions regarding US9186444B2 and US9138216B2 entirely open for the San Antonio Division.
Intra-district transfer: what moving to San Antonio means for the case
What an intra-district transfer under § 1404(b) means
Under 28 U.S.C. § 1404(b), a district court may transfer a civil action to any other division within the same district on a joint motion of the parties. No change of jurisdiction occurs — the case remains in the Western District of Texas — but the receiving division (here, San Antonio) will now manage all future proceedings, including scheduling, claim construction, and trial.
Venue shift, same districtMeditech's infringement claims survive and continue in San Antonio
The transfer does not resolve or dismiss Meditech's infringement claims. Both US9186444B2 and US9138216B2 remain asserted against Solventum's NPWT product lines. Meditech agreed to the transfer jointly, suggesting the San Antonio Division is acceptable or preferable. All substantive rights — including the ability to seek damages and injunctive relief — are preserved.
Claims intact, litigation continuesSolventum faces the same infringement exposure in a new division
Solventum co-filed the transfer motion, indicating agreement on venue. The move to San Antonio does not constitute any admission on the merits, nor does it resolve infringement or validity of the asserted patents. Solventum's full defence on the merits — including any invalidity, non-infringement, or licence arguments — remains available in the San Antonio Division.
Defences fully preservedHigh-value NPWT product lines remain under active litigation threat
Solventum's accused product portfolio — including V.A.C. Ulta, Veraflo, Prevena, AbThera, SensaT.R.A.C., and VeraT.R.A.C. — covers a broad range of commercially significant NPWT therapy systems. With the case now in San Antonio, competitors and suppliers in the NPWT space should monitor docket activity closely, as claim construction and any injunctive relief rulings could carry sector-wide implications.
NPWT sector risk remains liveFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Meditech Development, Inc. | Company | /Search in Eureka ↗ |
| Defendant | Solventum Corporation | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Brian S. Seal | Attorney | Counsel for Meditech Development, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Mark D. Siegmund | Attorney | Counsel for Meditech Development, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Thomas G. Southard | Attorney | Counsel for Meditech Development, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Cherry Johnson Siegmund James PLLC | Law Firm | Representing Meditech Development, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing Meditech Development, Inc.Search in Eureka ↗ |
| Defendant counsel | Aaron D. Bray | Attorney | Counsel for Solventum CorporationSearch in Eureka ↗ |
| Defendant counsel | Aimee Vidaurri | Attorney | Counsel for Solventum CorporationSearch in Eureka ↗ |
| Defendant counsel | Colette Elizabeth Verch | Attorney | Counsel for Solventum CorporationSearch in Eureka ↗ |
| Defendant counsel | Deborah J. Swedlow | Attorney | Counsel for Solventum CorporationSearch in Eureka ↗ |
| Defendant counsel | Kathryn Lauren Cantu | Attorney | Counsel for Solventum CorporationSearch in Eureka ↗ |
| Defendant counsel | Ron N. Sklar | Attorney | Counsel for Solventum CorporationSearch in Eureka ↗ |
| Defendant counsel | Scott D. Barnett | Attorney | Counsel for Solventum CorporationSearch in Eureka ↗ |
| Defendant law firm | Honigman LLP | Law Firm | Representing Solventum CorporationSearch in Eureka ↗ |
| Defendant law firm | Norton Rose Fulbright LLP | Law Firm | Representing Solventum CorporationSearch in Eureka ↗ |
| Defendant law firm | Norton Rose Fulbright US LLP | Law Firm | Representing Solventum CorporationSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Texas Western District CourtSearch in Eureka ↗ |
R&D signals in the negative pressure wound therapy patent space
Forward-looking patent and innovation intelligence derived from Meditech v. Solventum — tracking NPWT filing trends, portfolio activity, and white-space opportunities.
Meditech's NPWT patent portfolio: how deep does it run?
Meditech has asserted two NPWT patents originating from application numbers in the US13/7xxxxx series, suggesting filings from the early-to-mid 2010s. Understanding whether Meditech holds additional continuations, divisionals, or related family members in the NPWT space is critical for any company operating in this therapy category.
Plaintiff IP depthFiling trends in NPWT tubing and therapy delivery systems
Negative pressure wound therapy has seen sustained patent activity as device makers compete on therapy precision, tubing design, and multi-modality wound management. Mapping recent filing trends around NPWT tubing assemblies, wound dressings, and therapy unit architectures can reveal where competitors are investing and where design-around space may exist.
NPWT filing trendsSolventum's NPWT patent position and defensive portfolio
Solventum — the medical technology company spun off from 3M's health care division — operates one of the most extensive NPWT product portfolios globally. Understanding Solventum's own patent holdings in NPWT systems, wound dressings, and topical wound solution delivery may reveal how it is positioned to assert defensive claims or challenge Meditech's patents on invalidity grounds.
Solventum defensive IPAdjacent NPWT innovation opportunities near the asserted claim scope
With two Meditech patents covering core NPWT system and tubing configurations, R&D teams should map adjacent white space — including smart sensor-enabled wound monitoring, antimicrobial dressing integration, and portable NPWT unit architectures — where patent density may be lower and freedom-to-operate risk is reduced.
NPWT design-around spaceSimilar NPWT patent infringement cases in the Western District of Texas
Explore comparable negative pressure wound therapy patent infringement actions filed in the Western District of Texas, including intra-district transfers and contested venue decisions.
What this case signals for the NPWT and wound therapy IP landscape
A joint venue transfer in the first 70 days rarely signals weakness — it signals strategy. Both sides chose their battlefield.
Joint § 1404(b) transfers signal bilateral venue preference — watch San Antonio docket
When both parties co-move for an intra-district transfer, it typically signals agreement that the new division offers procedural advantages neither side contested. IP teams monitoring NPWT litigation should now track the San Antonio Division docket for scheduling orders and claim construction hearings, which will define the real scope of the dispute.
Two NPWT patents covering tubing, dressings, and therapy units — broad claim scope risk
US9186444B2 and US9138216B2 together cover multiple elements of NPWT delivery systems. Competitors developing negative pressure wound therapy hardware, tubing assemblies, or therapy units should assess whether their designs fall within the claims of either patent before the San Antonio court reaches claim construction.
Meditech v Solventum — key questions answered
Meditech Development asserted US9186444B2 (application US13/797968) and US9138216B2 (application US13/751343) against Solventum Corporation in a patent infringement action filed March 26, 2026 in the Western District of Texas.
The accused products include SensaT.R.A.C., VeraT.R.A.C., VeraT.R.A.C. Duo tubing, V.A.C. Ulta and V.A.C. Ulta 4 NPWT units used with V.A.C. Therapy, Veraflo Therapy, Prevena Therapy and AbThera Therapy, topical wound solutions for Veraflo Therapy, and associated wound dressings sold as kits and separately.
The case was transferred on a joint motion filed by both parties under 28 U.S.C. § 1404(b), which allows intra-district transfer by consent. The court granted the motion and directed the Clerk to transfer the case to the San Antonio Division of the Western District of Texas without delay. The specific reasons the parties preferred San Antonio are not disclosed in the available public record.
No. The transfer is purely procedural and resolves only the question of which division will hear the case. All substantive infringement claims regarding US9186444B2 and US9138216B2 remain pending and will be litigated in the San Antonio Division. No merits ruling, claim construction, or infringement finding was issued.
Companies developing or commercialising NPWT systems, tubing assemblies, wound dressings, or related therapy delivery products should monitor claim construction proceedings in the San Antonio Division. The breadth of accused products across multiple Solventum therapy brands suggests the asserted patents may cover widely used NPWT configurations, creating potential FTO risk for others in the sector.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.